Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre randomized, vehicle-controlled clinical study

Efficacy And Safety ◽

Japanese Adult ◽

Janus Kinase Inhibitor ◽

Controlled Clinical Study

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study

British Journal of Dermatology ◽

10.1111/bjd.16014 ◽

2018 ◽

Vol 178 (2) ◽

pp. 424-432 ◽

Cited By ~ 59

Author(s):

H. Nakagawa ◽

O. Nemoto ◽

A. Igarashi ◽

T. Nagata

Keyword(s):

Atopic Dermatitis ◽

Clinical Study ◽

Phase Ii ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Japanese Adult ◽

Janus Kinase Inhibitor ◽

Controlled Clinical Study

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study

10.1016/j.jaad.2019.06.224 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB53

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Pediatric Patients ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

American Journal of Clinical Dermatology ◽

10.1007/s40257-021-00627-2 ◽

2021 ◽

Author(s):

Yan Zhao ◽

Litao Zhang ◽

Yangfeng Ding ◽

Xiaohua Tao ◽

Chao Ji ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Randomized Clinical Trial ◽

Phase Ii ◽

Janus Kinase ◽

Efficacy And Safety ◽

Janus Kinase 1

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Cited By ~ 19

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

The Journal of Dermatology ◽

10.1111/1346-8138.15173 ◽

2019 ◽

Vol 47 (2) ◽

pp. 114-120 ◽

Cited By ~ 8

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Ryusei Murata ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Adult Patients ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Reumatología Clínica (English Edition) ◽

10.1016/j.reumae.2017.04.009 ◽

2019 ◽

Vol 15 (1) ◽

pp. 43-53

Author(s):

Ruben Burgos-Vargas ◽

Mario Cardiel ◽

Daniel Xibillèc) ◽

Cèc)sar Pacheco-Tena ◽

Virginia Pascual-Ramos ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Phase 3 ◽

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

10.1016/j.jaad.2016.01.013 ◽

2016 ◽

Vol 74 (5) ◽

pp. 841-850 ◽

Cited By ~ 78

Author(s):

Kim A. Papp ◽

James G. Krueger ◽

Steven R. Feldman ◽

Richard G. Langley ◽

Diamant Thaci ◽

...

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies